Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 25, 2025 05:24 ET | Source: Merus N.V.

Tussentijdse gegevens van Merus over petosemtamab bij gemetastaseerde colorectale kanker tonen monotherapie-activiteit en robuust responspercentage aan in combinatie met FOLFOX/FOLFIRI, alsook goed verdragen veiligheid

– 100% responspercentage in 1L linkszijdige mCRC (n=8, bevestigd en onbevestigd) – 62% responspercentage in 2L links- en rechtszijdige mCRC (n=13, bevestigd en onbevestigd) UTRECHT, Nederland...
October 24, 2025 10:00 ET | Source: Merus N.V.

Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety

– 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) UTRECHT, The Netherlands and...
October 14, 2025 14:43 ET | Source: Merus N.V.

Op de AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics kondigt Merus de publicatie aan van het abstract over petosemtamab in gemetastaseerde colorectale kanker

- In combinatie met FOLFOX/FOLFIRI (1L en 2L mCRC) en als monotherapie (3L+ mCRC) toont petosemtamab werkzaamheid tegen tumoren en een beheerbaar veiligheidsprofiel aan UTRECHT, Nederland en...
October 14, 2025 07:30 ET | Source: Merus N.V.

Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

- Petosemtamab in combination with FOLFOX /FOLFIRI (1L and 2L mCRC) and as monotherapy (3L+ mCRC), demonstrates antitumor activity and a manageable safety profile UTRECHT, The Netherlands and...
October 13, 2025 12:00 ET | Source: Merus N.V.

Merus kondigt de selectie aan van het abstract: Petosemtamab in Metastatic Colorectal Cancer (petosemtamab in gemetastaseerde colorectale kanker) voor mondelinge presentatie in de plenaire sessie op de AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

- Mondelinge presentatie plenaire sessie: vrijdag 24 oktober 10.00 - 11.40 uur. ET - Posterpresentatie over preklinische evaluatie van petosemtamab op kankerstamcellen: vrijdag 24 oktober 12.30 -...
October 13, 2025 12:00 ET | Source: Merus N.V.

Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

- Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET - Poster presentation on preclinical evaluation of petosemtamab on cancer stem cells: Friday, October 24 12:30-4:00...
August 28, 2025 08:00 ET | Source: Merus N.V.

Merus to Present at the 2025 Wells Fargo Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and...
August 07, 2025 15:24 ET | Source: Merus N.V.

Merus gibt die Finanzergebnisse für das zweite Quartal 2025 bekannt und informiert über die aktuelle Geschäftsentwicklung

– Petosemtamab in Kombination mit Pembrolizumab als Erstlinienbehandlung des PD-L1-positiven rezidivierenden/metastasierten Plattenepithelkarzinoms des Kopfes und Halses zeigt in Phase-II-Studie eine...
August 07, 2025 15:24 ET | Source: Merus N.V.

Merus annonce ses résultats financiers pour le deuxième trimestre 2025 et fait le point sur ses activités

- Le pétosemtamab en association avec le pembrolizumab dans un essai de phase 2 mené chez 43 patients atteints d’un CETC r/m PD-L1+ en première intention a permis d’obtenir un taux de réponse de 63 %...
August 06, 2025 08:00 ET | Source: Merus N.V.

Merus to Present at the Canaccord Genuity 45th Annual Growth Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and...